GeneDx: Why I Think The Selloff Went Too Far
GeneDx shares have collapsed 65% since November, but I assign a buy rating due to strong volume growth and undervaluation versus peers. Despite a 34% YoY volume increase, revenue growth lagged at 27% due to lower reimbursement rates from a shift to genome testing. WGS owns one of the largest rare disease genomic databases, creating a durable competitive advantage and potential for AI-driven value creation.
GeneDx Holdings Corp. (WGS) Reports Q1 Loss, Lags Revenue Estimates
GeneDx Holdings Corp. (WGS) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.28 per share a year ago.
Will Robust Exome and Genome Revenues Lift GeneDx's Q1 Earnings?
GeneDx heads into Q1 earnings results with strong exome and genome momentum, supported by expanding adoption and a growing rare-disease data advantage.
GENEDX HOLDINGS (WGS) Upgraded to Strong Buy: Here's What You Should Know
GENEDX HOLDINGS (WGS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Financial Contrast: GeneDx (NASDAQ:WGS) & Amarantus Bioscience (OTCMKTS:AMBS)
GeneDx (NASDAQ: WGS - Get Free Report) and Amarantus Bioscience (OTCMKTS:AMBS - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, earnings, risk, dividends and analyst recommendations. Analyst Recommendations This is a summary of current ratings
100,284 Shares in GeneDx Holdings Corp. $WGS Bought by Capital International Investors
Capital International Investors acquired a new position in GeneDx Holdings Corp. (NASDAQ: WGS) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 100,284 shares of the company's stock, valued at approximately $10,805,000. Capital International Investors owned 0.35% of GeneDx
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C
GeneDx launches Zevra-backed testing program to expand ExomeDx access for Niemann-Pick Type C, aiming to speed diagnosis and add data to its Infinity dataset.
Wall Street Analysts Believe GENEDX HOLDINGS (WGS) Could Rally 77.81%: Here's is How to Trade
The consensus price target hints at a 77.8% upside potential for GENEDX HOLDINGS (WGS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
GeneDx: The Growth Story Isn't Dead, It's Changing (Rating Upgrade)
GeneDx (WGS) is upgraded to 'Buy' as valuation resets and operational improvements support a more realistic growth outlook. Per my DCF model, WGS now targets 25% CAGR and 10% free cash flow margins, with potential to reach 14% FCF margin, making its valuation less stretched. Management plans to nearly triple its commercial footprint in 2026, prioritizing growth capture over near-term margins and signaling a ramp toward 2027 acceleration.
GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
GeneDx Holdings Corp. (WGS) Q4 2025 Earnings Call Transcript
GeneDx Holdings Corp. (WGS) Q4 Earnings and Revenues Beat Estimates
GeneDx Holdings Corp. (WGS) came out with quarterly earnings of $0.14 per share, beating the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.7 per share a year ago.
GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
GeneDx Holdings Corp. (WGS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
